Embecta Corp.· EMBC
🇺🇸 US · MicroSP600NASDAQ
- Price
- $3.82
- Day
- +2.69%
- Mkt Cap
- $226.63M
- 52W Range
- $2.77 – $15.55
- Volume
- 1.04M
- Beta
- 0.81
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
New York, New York--(Newsfile Corp. - August 4, 2026) - Bronstein, Gewirtz and Grossman, LLC, a nationally recognized investor-rights law
Read full article
NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Embecta Corp. (“Embecta” or the “Company”) (NASDAQ: EMBC). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
Read full article
NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Embecta Corp. (NASDAQ: EMBC) between November 25, 2025 and May 4, 2026, inclusive (the “Class Period”), of the important August 17, 2026 lead plaintiff deadline. SO WHAT: If you purchased Embecta common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Read full article
NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the common stock of Embecta Corp. (“Embecta” or the “Company”) (NASDAQ: EMBC) between November 25, 2025 and May 4, 2026, inclusive. Should You Join The Embecta Class Action Lawsuit : Do you, or did you, own shares of Embecta Corp. (NASDAQ: EMBC)?
Read full article
NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Embecta Corp. (NASDAQ: EMBC) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Embecta securities between November 25, 2025 and May 4, 2026, both dates inclusive (the “Class Period”).
Read full article
Embecta Promised Investors Flat-to-Down-2% Revenue and $2.80–$3.00 EPS — Then Delivered a 17.4% Revenue Collapse and Slashed Earnings Guidance by Nearly Half Embecta Promised Investors Flat-to-Down-2% Revenue and $2.80–$3.00 EPS — Then Delivered a 17.4% Revenue Collapse and Slashed Earnings Guidance by Nearly Half
Read full article
LOS ANGELES, Aug. 04, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Embecta Corp., (“Embecta” or the "Company") (NASDAQ: EMBC) investors of a class action on behalf of investors that bought securities between November 25, 2025 and May 4, 2026, inclusive (the “Class Period”). Embecta investors have until August 17, 2026 to file a lead plaintiff motion.
Read full article
SAN FRANCISCO, Aug. 4, 2026 /PRNewswire/ -- Hagens Berman, a leading national shareholder rights law firm, is conducting an investigation into Embecta Corp. (NASDAQ: EMBC) regarding alleged violations of federal securities laws. This investigation follows the recent filing of a class action lawsuit in the U.S. District Court for the District of New Jersey, which alleges that Embecta misrepresented the commercial stability of its insulin pen needle business.
Read full article
NEW YORK, Aug. 4, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Embecta Corp. (NASDAQ: EMBC). Shareholders who purchased shares of EMBC during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
Read full article
A securities fraud class action lawsuit has been filed on behalf of Embecta investors after its stock plummeted over 57% because Embecta allegedly misled investors regarding the strength of its insulin pen needle product category. NEW YORK, Aug. 4, 2026 /PRNewswire/ -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Embecta Corp. (NASDAQ:EMBC) and certain of the Company's senior executives for securities fraud after its significant stock drop resulting from potential violations of the federal securities laws.
Read full article
SAN FRANCISCO, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Hagens Berman, a leading national shareholder rights law firm, is conducting an investigation into Embecta Corp. (NASDAQ: EMBC) regarding alleged violations of federal securities laws. This investigation follows the recent filing of a class action lawsuit in the U.S. District Court for the District of New Jersey, which alleges that Embecta misrepresented the commercial stability of its insulin pen needle business.
Read full article
Wall Street Turned Bearish on Embecta After a "Major Miss" Exposed the Gap Between Management's "Incredibly Resolute" Pen Needle Claims and a 57.8% Single-Day Stock Collapse Wall Street Turned Bearish on Embecta After a "Major Miss" Exposed the Gap Between Management's "Incredibly Resolute" Pen Needle Claims and a 57.8% Single-Day Stock Collapse
Read full article